Article
Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Nov 2009
Ma B B Y, Hui E P, Wong S C C, Tung S Y, Yuen K K, King A, Chan S L, Leung S F, Kam M K, Yu B K H, Zee B, Chan A T C
Abstract excerpt
BACKGROUND: Nasopharyngeal carcinoma (NPC) is a platinum-sensitive cancer and excision repair cross-complementing group 1 (ERCC1) polymorphisms have been shown to predict survival in several cancers following platinum therapy. PATIENTS AND METHODS: This multicenter study evaluated the activity of oxaliplatin and prolonged infusion of gemcitabine ('GEMOX' regimen) in recurrent NPC. Baseline blood samples were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.